Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Rilzabrutinib in Hepatic Impairment
NCT06444204Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rilzabrutinib in immune thrombocytopenia (ITP) and pemphigus vulgaris (PV) (3 arms), sponsored by Sanofi. Primary endpoints: Area under the concentration-time curve of total rilzabrutinib in plasma from 0 to t up to 30 hours, Area under the concentration-time curve of total rilzabrutinib in plasma from 0 to infinity up to 30 hours and 5 more. Started Nov 2020; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT06444204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444204.